Quantitative Risk Assessment on the Public Health Impact of Vibrio parahaemolyticus in Raw Oysters; Notice of Public Meeting, 41772 [05-14294]
Download as PDF
<![CDATA[
41772
Federal Register / Vol. 70, No. 138 / Wednesday, July 20, 2005 / Notices
grant announcements in the Federal
Register. Beginning October 1, 2005,
applicants will be able to find a
synopsis of all ACF grant opportunities
and apply electronically for
opportunities via: https://
www.Grants.gov. Applicants will also be
able to find the complete text at
https://www.acf.hhs.gov/grants/
index.html.
Please reference Section IV.3 for
details about acknowledgement of
received applications.
Dated: July 13, 2005.
Josephine B. Robinson,
Director, Office of Community Services.
[FR Doc. 05–14193 Filed 7–19–05; 8:45 am]
BILLING CODE 4184–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 1999N–1075] (formerly 99N–
1075)
Quantitative Risk Assessment on the
Public Health Impact of Vibrio
parahaemolyticus in Raw Oysters;
Notice of Public Meeting
AGENCY:
Food and Drug Administration,
Registration and Requests for Oral
Presentation: Send registration
information (including name, title, firm
name, address, telephone, and fax
number), and written materials to the
contact person by August 10, 2005.
Interested persons may present data,
information, or views orally or in
writing, on the issue. If you desire to
make a formal oral presentation, you
should notify the contact person before
August 10, 2005, and be prepared to
give a brief description of the general
nature of the information you wish to
present. Time allotted for each
presentation may be limited.
If you need special accommodations
due to a disability, please contact
Melissa Ellwanger at least 7 days in
advance of the meeting.
Transcripts: Transcripts of the
meeting may be requested in writing
from the Freedom of Information Office
(HFI–35), Food and Drug
Administration, 5600 Fishers Lane, rm.
12A–16, Rockville, MD 20857,
approximately 15 working days after the
meeting at a cost of 10 cents per page.
Dated: July 8, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–14294 Filed 7–18–05; 8:45 am]
BILLING CODE 4160–01–S
HHS.
ACTION:
Notice of public meeting.
The Food and Drug Administration
(FDA) is announcing a public meeting to
present the ‘‘Quantitative Risk
Assessment on the Public Health Impact
of Vibrio parahaemolyticus in Raw
Oysters.’’ This public meeting is
intended to provide clarification about
the results of the risk assessment and
information on how the risk assessment
may be utilized. Stakeholders will have
an opportunity to ask questions about
the risk assessment. Questions may also
be submitted in advance of the public
meeting (see Contact section of this
document). Elsewhere in this issue of
the Federal Register, FDA is
announcing the availability of the risk
assessment that is being presented at
this public meeting.
Date and Time: The meeting will be
held on August 13, 2005, from 12 noon
to 3 p.m.
Location: The meeting will be held at
the Grand Hotel Marriot Resort, One
Grand Blvd., Point Clear, AL 36564.
Contact: Melissa Ellwanger, Center for
Food Safety and Applied Nutrition
(HFS–417), Food and Drug
Administration, 5100 Paint Branch
Pkwy., College Park, MD 20740, 301–
436–1401, FAX: 301–436–2599, e-mail:
mellwang@cfsan.fda.gov.
VerDate jul<14>2003
14:24 Jul 19, 2005
Jkt 205001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 1999N–1075] (formerly 99N–
1075)
Quantitative Risk Assessment on the
Public Health Impact of Pathogenic
Vibrio parahaemolyticus in Raw
Oysters; Risk Assessment; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a risk assessment entitled
‘‘Quantitative Risk Assessment on the
Public Health Impact of Pathogenic
Vibrio parahaemolyticus in Raw
Oysters.’’ The quantitative risk
assessment will help the agency
evaluate risk mitigation strategies and
develop effective guidance for the
industry. Elsewhere in this issue of the
Federal Register, FDA is announcing a
public meeting to provide clarification
about the results of the risk assessment
and information about how the risk
assessment may be utilized.
ADDRESSES: Submit written requests for
single copies of the risk assessment
PO 00000
Frm 00094
Fmt 4703
Sfmt 4703
document and CD–ROM of the model to
Sherri Dennis, Center for Food Safety
and Applied Nutrition (see FOR FURTHER
INFORMATION CONTACT). Send one selfaddressed label to assist that office in
processing your request. You also may
request a copy of the risk assessment
document and model by fayour name
and mailing address with the name of
the document you are requesting to the
CFSAN Outreach and Information
Center at 1–877–366–3322. See the
SUPPLEMENTARY INFORMATION section for
electronic access to this document.
A copy of the risk assessment
document may be reviewed at the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville,
MD 20852, between 9 a.m. and 4 p.m.,
Monday through Friday.
FOR FURTHER INFORMATION CONTACT:
Sherri B. Dennis, Center for Food Safety
and Applied Nutrition (HFS–006), Food
and Drug Administration, 5100 Paint
Branch Pkwy., College Park, MD 20740,
301–436–1903.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of January 19,
2001 (66 FR 5517), FDA announced the
availability of a draft risk assessment on
the relationship between Vibrio
parahaemolyticus in raw molluscan
shellfish, specifically raw oysters, and
human health. A public meeting was
held on March 20, 2001 (66 FR 13544,
March 6, 2001), to receive comments on
the technical aspects of the draft risk
assessment. Interested persons were
given until March 20, 2001, with
extensions to May 21, 2001 (66 FR
13546, March 6, 2001), and to July 18,
2001 (66 FR 33101, June 20, 2001), to
comment on the draft risk assessment.
Nine letters, containing one or more
comments, were received in response to
the draft risk assessment. The risk
assessment has been revised in response
to the public comments, newly available
data, and updated modeling techniques.
Elsewhere in this issue of the Federal
Register, FDA is announcing a public
meeting to provide clarification about
the results of the risk assessment and
information about how the risk
assessment may be utilized.
II. Risk Assessment
The purpose of the quantitative risk
assessment is to examine systematically
available scientific data and information
to estimate the risk of illness associated
with consumption of raw oysters that
contain pathogenic V.
parahaemolyticus. This examination of
the current science and the models
E:\FR\FM\20JYN1.SGM
20JYN1
]]>Agencies
[Federal Register Volume 70, Number 138 (Wednesday, July 20, 2005)]
[Notices]
[Page 41772]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-14294]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 1999N-1075] (formerly 99N-1075)
Quantitative Risk Assessment on the Public Health Impact of
Vibrio parahaemolyticus in Raw Oysters; Notice of Public Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public meeting.
-----------------------------------------------------------------------
The Food and Drug Administration (FDA) is announcing a public
meeting to present the ``Quantitative Risk Assessment on the Public
Health Impact of Vibrio parahaemolyticus in Raw Oysters.'' This public
meeting is intended to provide clarification about the results of the
risk assessment and information on how the risk assessment may be
utilized. Stakeholders will have an opportunity to ask questions about
the risk assessment. Questions may also be submitted in advance of the
public meeting (see Contact section of this document). Elsewhere in
this issue of the Federal Register, FDA is announcing the availability
of the risk assessment that is being presented at this public meeting.
Date and Time: The meeting will be held on August 13, 2005, from 12
noon to 3 p.m.
Location: The meeting will be held at the Grand Hotel Marriot
Resort, One Grand Blvd., Point Clear, AL 36564.
Contact: Melissa Ellwanger, Center for Food Safety and Applied
Nutrition (HFS-417), Food and Drug Administration, 5100 Paint Branch
Pkwy., College Park, MD 20740, 301-436-1401, FAX: 301-436-2599, e-mail:
mellwang@cfsan.fda.gov.
Registration and Requests for Oral Presentation: Send registration
information (including name, title, firm name, address, telephone, and
fax number), and written materials to the contact person by August 10,
2005. Interested persons may present data, information, or views orally
or in writing, on the issue. If you desire to make a formal oral
presentation, you should notify the contact person before August 10,
2005, and be prepared to give a brief description of the general nature
of the information you wish to present. Time allotted for each
presentation may be limited.
If you need special accommodations due to a disability, please
contact Melissa Ellwanger at least 7 days in advance of the meeting.
Transcripts: Transcripts of the meeting may be requested in writing
from the Freedom of Information Office (HFI-35), Food and Drug
Administration, 5600 Fishers Lane, rm. 12A-16, Rockville, MD 20857,
approximately 15 working days after the meeting at a cost of 10 cents
per page.
Dated: July 8, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05-14294 Filed 7-18-05; 8:45 am]
BILLING CODE 4160-01-S
